Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Nanosonics Ltd (NAN AU): Two Upcoming Catalysts to Set Future Direction

Nanosonics Ltd (NAN AU): Steering Back to Growth Trajectory; Outlook Is Improving

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/nanosonics-ltd" target="_blank" data-smartkarma-citation="entities:3831:1" rel="noopener">Nanosonics Ltd (NAN AU)</a> reported strong performance for FY25, with revenue increasing 14%, matching the higher end of the revised FY25 revenue growth guidance of 11–14%.</li>
<li>Trophon3 and trophon2 Plus have now been launched in the U.S., Canada, UK, Ireland, Australia, and New Zealand. Coris should see controlled market release throughout FY26.</li>
<li>Nanosonics has guided for FY26 constant currency revenue of A$215–223M, up 8–12% YoY. Considering higher tariff impact, FY26 gross profit margin is expected at 75–77%.</li>
</ul>



Nanosonics Ltd (NAN AU) reported strong performance for FY25, with revenue increasing 14%, matching the higher end of the revised FY25 revenue growth guidance of 11–14%.
Trophon3 and trophon2 Plus have now been launched in the U.S., Canada, UK, Ireland, Australia, and New Zealand. Coris should see controlled market release throughout FY26.
Nanosonics has guided for FY26 constant currency revenue of A$215–223M, up 8–12% YoY. Considering higher tariff impact, FY26 gross profit margin is expected at 75–77%.


Nanosonics Ltd(NAN AU): 견고한 기반과 신규 출시로 2026 회계연도 성장 견인